

## Medical Coverage Policy | Intensity-Modulated Radiotherapy: Abdomen, Pelvis and Chest



**EFFECTIVE DATE:** 12|01|2022  
**POLICY LAST UPDATED:** 08|17|2022

### OVERVIEW

Radiotherapy may be an integral component of the treatment of cancers of the abdomen and pelvis. Intensity-modulated radiotherapy (IMRT) has been proposed as a method that allows adequate radiation to the tumor while minimizing the radiation dose to surrounding normal tissues and critical structures.

### MEDICAL CRITERIA

#### Medicare Advantage Plans and Commercial Products

Intensity-modulated radiotherapy may be considered **medically necessary** as an approach to delivering radiotherapy for individuals with cancer of the anus/anal canal.

When dosimetric planning with standard 3-dimensional conformal radiotherapy predicts that the radiation dose to an adjacent organ would result in unacceptable normal tissue toxicity, IMRT may be considered **medically necessary** for the treatment of cancer of the abdomen and pelvis, including but not limited to:

- stomach (gastric);
- hepatobiliary tract;
- pancreas;
- rectal locations; or
- gynecologic tumors (including cervical, endometrial, and vulvar cancers).

### PRIOR AUTHORIZATION

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products via the online tool for participating providers.

### POLICY STATEMENT

#### Medicare Advantage Plans and Commercial Products

Intensity-modulated radiotherapy of the abdomen and pelvis may be considered medically necessary when the criteria above has been met.

IMRT is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products for all other uses in the abdomen and pelvis.

### COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable radiology benefits/coverage.

### BACKGROUND

#### Radiation Techniques

##### Conventional External-Beam Radiotherapy

Methods to plan and deliver radiotherapy have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used 2-dimensional treatment planning, based on flat images and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along 2 or 3 intersecting axes. Collectively, these methods are termed conventional external-beam radiotherapy.

##### Three-Dimensional Conformal Radiation

Treatment planning evolved by using 3-dimensional images, usually from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed 3-dimensional conformal radiotherapy (3D-CRT).

### **Intensity-Modulated Radiotherapy**

IMRT uses computer software and CT and magnetic resonance images, to offer better conformality than 3D-CRT, because it modulates the intensity of the overlapping radiation beams projected on the target and uses multiple shaped treatment fields. Treatment planning and delivery are more complex, time-consuming, and labor intensive for IMRT than for 3D-CRT. The technique uses a multileaf collimator [MLC]), which, when coupled with a computer algorithm, allows for “inverse” treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target’s prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor, surrounding tissues, and organs at risk, computer software optimizes the location, shape, and intensities of the beam ports to achieve the treatment plan’s goals.

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing.

Technologic development has produced advanced techniques that may further improve RT treatment by improving dose distribution. These techniques are considered variations of IMRT. Volumetric modulated arc therapy delivers radiation from a continuous rotation of the radiation source. The principal advantage of volumetric modulated arc therapy is greater efficiency in treatment delivery time, reducing radiation exposure and improving target radiation delivery due to less patient motion. Image-guided RT involves the incorporation of imaging before and/or during treatment to more precisely deliver RT to the target volume.

IMRT methods to plan and deliver RT are not uniform. IMRT may use beams that remain on as MLCs move around the patient (dynamic MLC) or that are off during movement and turn on once the MLC reaches prespecified positions (“step and shoot” technique). A third alternative uses a very narrow single beam that moves spirally around the patient (tomotherapy). Each method uses different computer algorithms to plan treatment and yields somewhat different dose distributions in and outside the target. Patient position can alter target shape and thus affect treatment plans. Treatment plans are usually based on a single imaging scan, a static 3D-CT image. Current methods seek to reduce positional uncertainty for tumors and adjacent normal tissues by various techniques. Patient immobilization cradles and skin or bony markers are used to minimize day-to-day variability in patient positioning. In addition, many tumors have irregular edges that preclude drawing tight margins on CT scan slices when radiation oncologists contour the tumor volume. It is unknown whether omitting some tumor cells or including some normal cells in the resulting target affects outcomes of IMRT.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and the quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. Randomized

controlled trials are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Note that the evidence for the following abdominal and pelvic cancers has not yet been assessed and is beyond the scope of this review: bladder, kidney, and ureter cancer and sarcoma.

## **CODING**

### **Medicare Advantage Plans and Commercial Products**

**A4648** Tissue marker, implantable, any type, each (Note: This code is not separately reimbursed for institutional providers.)

**Note:** To ensure correct pricing of HCPC code **A4648** for the Calypso 4D localization system, the procedure/clinical notes and the invoice must be submitted.

The following codes are covered for Medicare Advantage Plans and Commercial Products when the criteria above is met:

- 77301** Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
- 77338** Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
- 77385** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple (Institutional providers)
- 77386** Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex (Institutional providers)
- G6015** Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session: (Professional providers)
- G6016** Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session: (Professional providers)

## **RELATED POLICIES**

Preauthorization via Web-Based Tool for Procedures  
Intensity Modulated Radiotherapy: Head, Neck and Thyroid  
Intensity Modulated Radiotherapy: Central Nervous System  
Intensity Modulated Radiotherapy: Breast and Lung  
Intensity Modulated Radiotherapy: Prostate

## **PUBLISHED**

Provider Update, October 2022  
Provider Update, November 2021  
Provider Update, January 2021  
Provider Update, October 2019  
Provider Update, December 2018

## **REFERENCES**

1. Misher C. Radiation therapy: which type is right for me?. Last reviewed: March 16, 2022. <https://www.oncolink.org/cancer-treatment/radiation/introduction-to-radiation-therapy/radiation-therapy-which-type-is-right-for-me>. Accessed June 1, 2022.
2. Ren F, Li S, Zhang Y, et al. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. *Radiat Oncol*. May 22 2019; 14(1): 84. PMID 31118042

3. Boda-Heggemann J, Hofheinz RD, Weiss C, et al. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. *Int J Radiat Oncol Biol Phys*. Nov 15 2009; 75(4): 1187-95. PMID 19409725
4. Boda-Heggemann J, Weiss C, Schneider V, et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. *Strahlenther Onkol*. May 2013; 189(5): 417-23. PMID 23558673
5. Fuller CD, Dang ND, Wang SJ, et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. *Radiother Oncol*. Aug 2009; 92(2): 249-54. PMID 19324442
6. Lee KJ, Yoon HI, Chung MJ, et al. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. *Gut Liver*. Mar 2016; 10(2):303-9. PMID 26470767
7. Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. *Pract Radiat Oncol*. Mar-Apr 2016; 6(2): 78-85. PMID 26577010
8. Lin Y, Chen K, Lu Z, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. *Radiat Oncol*. Sep 14 2018; 13(1): 177. PMID 30217165
9. Chopra S, Gupta S, Kannan S, et al. Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. *J Clin Oncol*. Nov 20 2021; 39(33): 3682-3692. PMID 34506246
10. Wortman BG, Post CCB, Powell ME, et al. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys*. Feb 01 2022; 112(2): 390-399. PMID 34610387
11. Klopp AH, Yeung AR, Deshmukh S, et al. Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203. *J Clin Oncol*. Aug 20 2018; 36(24): 2538-2544. PMID 29989857
12. Naik A, Gurjar OP, Gupta KL, et al. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. *Cancer Radiother*. Jul 2016; 20(5): 370-6. PMID 27368915
13. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. *Int J Radiat Oncol Biol Phys*. Nov 01 2013; 87(3): 542-8. PMID 24074927
14. Shih KK, Hajj C, Kollmeier M, et al. Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. *Gynecol Oncol*. Oct 2016; 143(1): 18-21. PMID 27486131
15. Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. *J Formos Med Assoc*. Dec 2014; 113(12): 949-55. PMID 24144528
16. Rattan R, Kapoor R, Bahl A, et al. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. *Ann Transl Med*. Feb 2016; 4(4): 70. PMID 27004217
17. Sun Z, Adam MA, Kim J, et al. Intensity-Modulated Radiation Therapy Is Not Associated with Perioperative or Survival Benefit over 3D-Conformal Radiotherapy for Rectal Cancer. *J Gastrointest Surg*. Jan 2017; 21(1): 106-111. PMID 27510332
18. Huang CM, Huang MY, Tsai HL, et al. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. *J Radiat Res*. Mar 01 2017; 58(2): 247-259. PMID 27738080
19. Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. *Gastrointest Cancer Res*. Mar 2013; 6(2): 39-45. PMID 23745158

20. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiation Oncology*. May 2013; 107(2): 189-94. PMID 23692961
21. Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?. *Radiation Oncology*. Nov 2012; 7: 201. PMID 23190693
22. Devisetty K, Mell LK, Salama JK, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. *Radiation Oncology*. Nov 2009; 93(2): 298-301. PMID 19717198
23. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. *International Journal of Radiation Oncology Biology Physics*. Dec 01 2010; 78(5): 1413-9. PMID 20231064
24. Xu D, Li G, Li H, et al. Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis. *Medicine (Baltimore)*. Aug 2017; 96(31): e7685. PMID 28767597
25. Lan K, Zhu J, Zhang J, et al. Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy. *Radiation Oncology*. Aug 2020; 149: 228-235. PMID 32474127
26. Ito M, Kodaira T, Tachibana H, et al. Clinical results of definitive chemoradiotherapy for cervical esophageal cancer: Comparison of failure pattern and toxicities between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy. *Head Neck*. Dec 2017; 39(12): 2406-2415. PMID 28960561
27. Haefner MF, Lang K, Verma V, et al. Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity. *Radiation Oncology*. Aug 15 2017; 12(1): 131. PMID 28810885
28. National Comprehensive Cancer Network. Gastric Cancer. Version. 2.2022. Updated January 11, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf). Accessed June 1, 2022.
29. National Comprehensive Cancer Network. Hepatobiliary Cancers. Version. 1.2022. Updated March 29, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf). Accessed June 1, 2022.
30. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma. Version 1.2022. Updated February 24, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf). Accessed June 1, 2022.
31. National Comprehensive Cancer Network. Cervical Cancer. Version. 1.2022. Updated October 26, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/cervical.pdf](https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf). Accessed June 2, 2022.
32. National Comprehensive Cancer Network. Uterine Neoplasms. Version 1.2022. Updated November 4, 2021. [https://www.nccn.org/professionals/physician\\_gls/pdf/uterine.pdf](https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf). Accessed June 4, 2022.
33. National Comprehensive Cancer Network. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. Version. 2.2022. Updated January 18, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed June 5, 2022.
34. National Comprehensive Cancer Network. Anal Carcinoma. Version. 1.2022. Updated March 2, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf). Accessed June 6, 2022.
35. National Comprehensive Cancer Network. Rectal Cancer. Version. 1.2022. Updated February 25, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). Accessed June 7, 2022.
36. National Comprehensive Cancer Network. Esophageal and esophagogastric junction cancers. Version 2.2022. Updated February 11, 2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/esophageal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf). Accessed June 3, 2022.
37. Chino J, Annunziata CM, Beriwal S, et al. Radiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*. Jul 2020; 10(4): 220-234. PMID 32473857
38. Wo JY, Anker CJ, Ashman JB, et al. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. *Practical Radiation Oncology*. Jan-Feb 2021; 11(1): 13-25. PMID 33097436

DRAFT

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

